Yi et al. found that activating the mutation of PI3K can result in ferroptosis resistance in tumor cells, while the expression of SREBP1 or SCD1 can inhibit the PI3K/Akt/mTOR axis by regulating lipid metabolism, which can sensitize the ferroptosis of cancer cells and play an antitumor role (Yi, et al., 2020). This evidence concerns the gene SREBF1 and cancer.